Discover a new level of trading with R MobileTrader<\/span>. Click on the button and install the award-winning app<\/p>\n <\/div>\n\n\n Year of registration:<\/strong> 2014<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> Branford, Connecticut<\/p>\n\n\n\n Sector:<\/strong> healthcare<\/p>\n\n\n\n Date of IPO<\/a>:<\/strong> 18 May 2023<\/p>\n\n\n\n Exchange<\/strong>:<\/strong> NYSE<\/p>\n\n\n\n Ticker:<\/strong> AZTR<\/p>\n\n\n\n Azitra Inc. develops drugs for the treatment of dermatological diseases.<\/p>\n\n\n\n Its main drugs are:<\/p>\n\n\n\n The amount of raised investment (as at 31 December 2022) is 33.7 million USD.<\/p>\n\n\n\n The main investors are BIOS Equity Partners LP, Bayer Healthcare LLC, and Connecticut Innovations Inc.<\/p>\n\n\n\n According to a Research and Markets report, the global Netherton syndrome treatment market in 2019 was valued at 19.6 million USD and is expected to reach 74.3 million USD by 2027. The compound annual growth rate (CAGR) is projected to be 20.3% from 2019-2027 inclusive.<\/p>\n\n\n\n According to Vision Research Reports, the global market of dermatological drugs was valued at 17 billion USD in 2021. The average annual expected growth rate from 2021 to 2030 inclusive is 8.8%.<\/p>\n\n\n\n Revenue in 2022 amounted to 284 thousand USD, +158%<\/p>\n\n\n\n Net loss in 2022 was 10.7 million USD, +19%<\/p>\n\n\n\n Net cash flow (as at 31 December 2022): -8.4 million USD<\/p>\n\n\n\n Cash and cash equivalents (as at 31 December 2022): 3.5 million USD<\/p>\n\n\n\n Liabilities (as at 31 December 2022): 9.7 million USD<\/p>\n\n\n\n Strengths:<\/p>\n\n\n\n Weaknesses:<\/p>\n\n\n\n Underwriter: ThinkEquity LLC<\/p>\n\n\n\n Offered stock volume: 2.4 million ordinary shares<\/a><\/p>\n\n\n\n Average price: 5 USD<\/p>\n\n\n\n Gross proceeds: 12 million USD, excluding the sale of options by the underwriter<\/p>\n\n\n\n Expected amount of capitalisation at the time of the IPO: 64.8 million USD<\/p>\n\n\n\n Potential P\/S<\/a> (capitalisation\/revenues): 228.02<\/p>\n\n\n\n Average P\/S value of diagnostic test producers: 9.64<\/p>\n\n\n\n Year of registration:<\/strong> 2014<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> West Palm Beach, Florida<\/p>\n\n\n\n Sector:<\/strong> healthcare<\/p>\n\n\n\n Date of IPO:<\/strong> 16 May 2023<\/p>\n\n\n\n Exchange<\/strong>:<\/strong> NASDAQ<\/p>\n\n\n\n Ticker:<\/strong> MLDS<\/p>\n\n\n\n MDNA Life Sciences Inc. develops and produces medical tests for diagnosing various diseases even in their early stages.<\/p>\n\n\n\n The amount of raised investment (as at 30 June 2022) is 28.7 million USD.<\/p>\n\n\n\n According to a report by Grand View Research, the global medical diagnostic tests market was valued at 2.8 billion USD in 2019 and could reach 7.6 billion USD by 2027. The average annual projected growth rate from 2020 to 2027 inclusive is 13.2%.<\/p>\n\n\n\n Revenue in the fiscal year that ended on 30 September 2022 amounted to 1.6 million USD, -56.9%<\/p>\n\n\n\n Net loss for the same period was 6.1 million USD, +102.2%<\/p>\n\n\n\n Net cash flow (as at 30 September 2022): -1.9 million USD<\/p>\n\n\n\n Cash and cash equivalents (as at 30 September 2022): 38.1 thousand USD<\/p>\n\n\n\n Liabilities (as at 30 September 2022): 25.4 million USD<\/p>\n\n\n\n Strengths:<\/p>\n\n\n\n Weaknesses:<\/p>\n\n\n\n Underwriter: EF Hutton, a division of Benchmark Investments LLC<\/p>\n\n\n\n Offered stock volume: 2.5 million ordinary shares<\/p>\n\n\n\n Average price: 5.5 USD<\/p>\n\n\n\n Gross proceeds: 13.7 million USD, excluding the sale of options by the underwriter<\/p>\n\n\n\n Expected amount of capitalisation at the time of the IPO: 51.95 million USD<\/p>\n\n\n\n Potential P\/S (capitalisation\/revenues): 33.52<\/p>\n\n\n\n Average P\/S of biotechnology companies: 3.04<\/p>\n\n\n\n Gain access to over 1000 US stocks for commission-free trading on the R StocksTrader<\/span> platform<\/p>\n <\/div>\n Year of registration:<\/strong> 2021<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> Charlotte, North Carolina<\/p>\n\n\n\n Sector:<\/strong> technologies<\/p>\n\n\n\n Date of IPO:<\/strong> 16 May 2023<\/p>\n\n\n\n Exchange<\/strong>:<\/strong> NYSE<\/p>\n\n\n\n Ticker:<\/strong> SGE<\/p>\n\n\n\n Strong Global Entertainment Inc. produces cinema projection screens and is the leader in this market. The company has partnerships with AMC Entertainment Holdings Inc., IMAX Corporation, and Cinemark Holdings Inc.<\/p>\n\n\n\n The amount of raised investment (as at 30 June 2022) is 13.8 million USD.<\/p>\n\n\n\n The main investor is Strong\/MDI Screen Systems Inc.<\/p>\n\n\n\n The outlook for Strong Global Entertainment's addressable market<\/p>\n\n\n\n According to an Insight Partners report, the global wide-screen cinema market was valued at 7.3 billion USD in 2020 and could reach 13.5 billion USD by 2027. The projected average annual growth rate from 2021 to 2027 inclusive is 9.6%.<\/p>\n\n\n\n Revenue in 2022 amounted to 39.9 million USD, +53.5%<\/p>\n\n\n\n Net profit in 2022 reached 1.7 million USD, +107.1%<\/p>\n\n\n\n Net cash flow (as at 30 June 2022): 0.82 million USD<\/p>\n\n\n\n Cash and cash equivalents (as at 30 June 2022): 3 million USD<\/p>\n\n\n\n Liabilities (as at 30 June 2022): 14.4 million USD<\/p>\n\n\n\n Strengths:<\/p>\n\n\n\n Weaknesses:<\/p>\n\n\n\n Underwriter: ThinkEquity LLC<\/p>\n\n\n\n Offered stock volume: 1.6 million ordinary shares<\/p>\n\n\n\n Average price: 5 USD<\/p>\n\n\n\n Gross proceeds: 8 million USD, excluding the sale of options by the underwriter<\/p>\n\n\n\n Expected amount of capitalisation at the time of the IPO: 38 million USD<\/p>\n\n\n\n Potential P\/S (capitalisation\/revenues): 0.95<\/p>\n\n\n\n Average P\/S value for manufacturers of wide screens: 2.47<\/p>\n\n\n\n Potential upside (stock growth potential): 160%<\/p>\n\n\n\n Try trading in the high-tech R StocksTrader<\/span> terminal!<\/p>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rmt-mobile.png\")
\n\n <\/div>\n ![](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/themes\/robo-blog-2021\/images\/footer\/google-play-en.svg\")
<\/a>\n\n ![](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/themes\/robo-blog-2021\/images\/footer\/app-store-en.svg\")
<\/a>\n <\/div>\n <\/div>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rmt-desktop.png\")
\n <\/div>\n <\/div>\n\n\n\n<\/a>1. Azitra Inc. IPO - 65 million USD<\/h2>\n\n\n
\n
![\"Stages of](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/8-aztr.png\")
<\/a><\/span><\/a>The outlook for Azitra’s addressable market<\/span><\/h3>\n\n\n\n
<\/span><\/a>Financial performance of Azitra<\/span><\/h3>\n\n\n\n
![\"Financial](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/9-aztr.png\")
<\/a><\/span><\/a>Azitra’s strengths and weaknesses<\/span><\/h3>\n\n\n\n
\n
\n
<\/span><\/a>Details of the Azitra IPO<\/span><\/h3>\n\n\n\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/prime-mobile.png\")
\n <\/div>\n Open a Prime Account<\/a>\n <\/div>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/prime-desktop.png\")
\n <\/div>\n <\/div>\n\n\n\n<\/a>2. IPO of MDNA Life Sciences Inc. - 52 million USD<\/h2>\n\n\n\n
<\/span><\/a>The outlook for the MDNA Life Sciences addressable market<\/span><\/h3>\n\n\n\n
![\"Addressable](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/5-mdls.png\")
<\/a><\/span>Financial performance of MDNA Life Sciences<\/span><\/h3>\n\n\n\n
![\"Financial](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/6-mdls.png\")
<\/a><\/span><\/a>Strengths and weaknesses of MDNA Life Sciences<\/span><\/h3>\n\n\n\n
\n
\n
<\/span><\/a>Details of the MDNA Life Sciences IPO<\/span><\/h3>\n\n\n\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/1free-stocks-mobile.png\")
\n <\/div>\n Start Now<\/a>\n <\/div>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/1free-stocks-descktop.png\")
\n <\/div>\n <\/div>\n\n\n\n<\/a>3. IPO of Strong Global Entertainment Inc. - 38 million USD<\/h2>\n\n\n
![\"The](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/2-sge.png\")
<\/a><\/span><\/a>Financial performance of Strong Global Entertainment<\/span><\/h3>\n\n\n\n
![\"Financial](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/05\/3-sge.png\")
<\/a><\/span><\/a>Strengths and weaknesses of Strong Global Entertainment<\/span><\/h3>\n\n\n\n
\n
\n
<\/span><\/a>Details of the Strong Global Entertainment IPO<\/span><\/h3>\n\n\n\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rst2-mobile.png\")
\n <\/div>\n Open R StocksTrader Account<\/a>\n <\/div>\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rst2-desktop.png\")
\n <\/div>\n <\/div>\n\n\n\n